{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-039392","form_type":"8-K/A","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.987700+00:00","generated_at":"2026-05-17T15:21:22.659880+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M","bullets":["Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.","U.S. net product revenue rose 42% Y/Y to $40.3M; total revenue grew 12% to $82.4M.","Achieved $7.1M operating income, first quarter of positive operating income from ongoing ops.","Reached ANDA settlements blocking generic bempedoic acid until 2040.","Cash $86.1M at June 30; expects sustainable profitability starting Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-039392","json":"https://secwatch.observer/filing/0001628280-25-039392.json","markdown":"https://secwatch.observer/filing/0001628280-25-039392.md","text":"https://secwatch.observer/filing/0001628280-25-039392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/0001628280-25-039392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025039392/espr-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:21:22.659880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}